Relapsed/Refractory Multiple Myeloma Q&A: MRD, High-Risk Maintenance & Survival

Description

In this relapsed/refractory breakout session at the HealthTree Houston Myeloma Roundtable (October 24, 2026), Dr. Meera Mohan answers patient questions about multiple myeloma. Topics include maintenance therapy for high-risk and TP53-mutated myeloma (lenalidomide alone vs. daratumumab or isatuximab combinations, clinical trials), how often to repeat cytogenetic testing and bone marrow biopsies, why a bone marrow test is done before CAR-T, whether blood tests can replace bone marrow for MRD, average lifespan and first-remission length, how to monitor non-secretory myeloma, and whether in vivo CAR-T is possible after two prior CAR-T therapies.